Academic literature on the topic 'LDL/HDL'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'LDL/HDL.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "LDL/HDL"
1
J.-M.M. "LDL, oui, mais HDL?" Revue Francophone des Laboratoires 2007, no. 392 (May 2007): 15. http://dx.doi.org/10.1016/s1773-035x(06)80621-0.
Full text
2
Amrullah, Amran, Budi Handono, and Akhmad Yogi Pramatirta. "Rasio Low Density Lipoprotein dan High Density Lipoprotein pada Preeklamsi Berat dibandingkan dengan Kehamilan Normal di Rumah Sakit Dr. Hasan Sadikin Bandung." Indonesian Journal of Obstetrics & Gynecology Science 2, no. 1 (March 29, 2019): 67. http://dx.doi.org/10.24198/obgynia.v2i1.79.
Full textAbstract:
AbstractObjective: This study aims to distinguish level of (LDL/HDL) and Low Density Lipoprotein/High Density Lipoprotein ratio in severe preeclampsia patient compared to normal pregnancy.Method: The study design was comparative cross-sectional study with consecutive sampling method that compared the laboratory results of LDL, HDL and ratio LDL/HDL that met the inclusion criteria. Subjects of this study were severe preeclampsia and normal pregnancy patient that fulfilled the inclusion criteria (n=60) in Dr. Hasan Sadikin General Hospital Bandung during August-September 2017.Result: It is revealed that the differences in level of LDL and LDL/HDL ratios in both groups were significant with p value ≤ 0,05. But there were no differences in HDL level. Increased level of LDL/HDL ratio in pregnancy was related to increased risk of preeclampsia with cut-off point> 2,632. If the increased level of LDL/HDL above cut-off point then the insident of severe preeclampsia increased 21,36 times.Conclusion: It was concluded that level of LDL and LDL/HDL ratios in severe preeclampsia were higher than in normal pregnancy. The increased LDL/HDL ratio of > 2.632 increased the risk of severe preeclampsia by 21.36 times.Perbandingan Rasio Low Density Lipoprotein/High Density Lipoprotein antara Preeklamsi Berat dan Kehamilan Normal di RSUP Dr. Hasan Sadikin BandungAbstrakTujuan: Penelitian ini adalah untuk mencari perbedaan rasio Low Density Lipoprotein/High Density Lipoprotein (LDL/HDL) pada preeklamsi berat dibandingkan dengan kehamilan normal sebagai faktor risiko timbulnya preeklamsi.Metode: Rancangan penelitian kasus kontrol membandingkan LDL, HDL, dan rasio LDL/HDL penderita preeklamsi berat dan kehamilan normal (n=60) bulan Agustus-September 2017 di Rumah Sakit Dr. Hasan Sadikin Bandung.Hasil: Hasil penelitian didapatkan perbedaan kadar LDL dan rasio LDL/HDL pada kedua kelompok secara bermakna dengan nilai p ≤0,05. Namun tidak didapatkan perbedaan yang bermakna pada kadar HDL. Peningkatan kadar LDL dan rasio LDL/HDL berhubungan dengan peningkatan risiko terjadinya preeklamsi dengan nilai cut-off > 2,632. Bila terjadi peningkatan rasio LDL/HDL diatas nilai cut-off maka risiko tejadinya preeklamsi berat sebesar 21,36 kali.Simpulan: Kadar LDL yang tinggi dan nilai cut-off rasio LDL/HDL >2,632 meningkatkan risiko terjadinya preeklamsi berat 21,36 kaliKata kunci: Preeklamsi, LDL, HDL, Rasio LDL/HDL
3
Fujihara, Kazuya, Hiroaki Suzuki, Akira Sato, Satoru Kodama, Yoriko Heianza, Kazumi Saito, Hitoshi Iwasaki, et al. "Circulating Malondialdehyde-Modified LDL-Related Variables and Coronary Artery Stenosis in Asymptomatic Patients with Type 2 Diabetes." Journal of Diabetes Research 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/507245.
Full textAbstract:
Aims. To elucidate the levels of malondialdehyde-modified LDL (MDA-LDL)-related variables for predicting coronary artery stenosis (CAS) by coronary CT angiography (CCTA) in asymptomatic patients with type 2 diabetes (T2DM).Methods. Enrolled were 36 Japanese patients with T2DM who underwent CCTA and in whom MDA-LDL levels were measured. Definition of CAS was luminal narrowing of ≥50%. Trends through tertiles of each MDA-LDL-related variable were analyzed with a general linear model. The ability of each MDA-LDL-related variable to predict CAS was compared to areas under the curve (AUCs) in receiver operating characteristic curve (ROC) analysis.Results. Seventeen patients had CAS. Each MDA-LDL-related variable was an independent predictor of CAS (P=0.039for MDALDL,P=0.013for MDA-LDL/LDL-C,P=0.047for MDA-LDL/HDL-C, andP=0.013for (MDA-LDL/LDL-C)/HDL-C). AUCs of MDA-LDL, MDA-LDL/LDL-C, MDA-LDL/HDL-C, and (MDA-LDL/LDL-C)/HDL-C were 0.675 (95% CI 0.496–0.854), 0.765 (0.602–0.927), 0.752 (0.592–0.913), and 0.799 (0.643–0.955), respectively, for predicting CAS. Trends throughout the tertiles showed significant associations between MDA-LDL/LDL-C, MDA-LDL/HDL-C, or (MDALDL/LDL-C)/HDL-C and CAS (P=0.003for MDA-LDL/LDL-C,P=0.042for MDA-LDL/HDL-C, andP=0.001for (MDA-LDL/LDL-C)/HDL-C).Conclusions. Data suggest that measurements of MDA-LDL/LDL-C, MDA-LDL/HDLC, and (MDA-LDL/LDL-C)/HDL-C are useful for predicting CAS.
4
Baruch, Lawrence, Valerie J. Chiong, Sanjay Agarwal, and Bhanu Gupta. "Discordance of Non-HDL and Directly Measured LDL Cholesterol: Which Lipid Measure is Preferred When Calculated LDL Is Inaccurate?" Cholesterol 2013 (April 23, 2013): 1–6. http://dx.doi.org/10.1155/2013/502948.
Full textAbstract:
Objective. To determine if non-HDL cholesterol (N-HDL) and directly measured LDL cholesterol (D-LDL) are clinically equivalent measurements. Patients and Methods. Eighty-one subjects recruited for 2 cholesterol treatment studies had at least 1 complete fasting lipid panel and D-LDL performed simultaneously; 64 had a second assessment after 4 to 6 weeks, resulting in 145 triads of C-LDL, D-LDL, and N-HDL. To directly compare N-HDL to D-LDL and C-LDL, we normalized the N-HDL by subtracting 30 from the N-HDL (N-HDLA). Results. There was significant correlation between N-HDLA, D-LDL, and C-LDL. Correlation was significantly greater between N-HDLA and C-LDL than between N-HDLA and D-LDL. A greater than 20 mg/dL difference between measures was observed more commonly between N-HDLA and D-LDL, 29%, than between C-LDL and N-HDLA, 11% (P<0.001), and C-LDL and D-LDL, 17% (P=0.028). Clinical discordance was most common, and concordance was least common between N-HDL and D-LDL. Conclusions. Our findings suggest that N-HDL cholesterol and D-LDL cholesterol are not clinically equivalent and frequently discordant. As N-HDL may be superior to even C-LDL for predicting events in statin-treated patients, utilizing N-HDL to guide therapy would appear to be preferable to D-LDL when C-LDL is inaccurate.
5
Garcia-Rios, Antonio, Dragana Nikolic, Pablo Perez-Martinez, Jose Lopez-Miranda, Manfredi Rizzo, and Ron Hoogeveen. "LDL and HDL Subfractions, Dysfunctional HDL: Treatment Options." Current Pharmaceutical Design 20, no. 40 (October 14, 2014): 6249–55. http://dx.doi.org/10.2174/1381612820666140620154014.
Full text
6
Benitez, S., C. Bancells, J. Ordonez-Llanos, and J. L. Sanchez-Quesada. "HDL COUNTERACTS INFLAMMATORY PROPERTIES OF ELECTRONEGATIVE LDL (LDL(-))." Atherosclerosis Supplements 9, no. 1 (May 2008): 50. http://dx.doi.org/10.1016/s1567-5688(08)70195-8.
Full text
7
Pian, M. S., and L. G. Dobbs. "Lipoprotein-stimulated surfactant secretion in alveolar type II cells: mediation by heterotrimeric G proteins." American Journal of Physiology-Lung Cellular and Molecular Physiology 273, no. 3 (September 1, 1997): L634—L639. http://dx.doi.org/10.1152/ajplung.1997.273.3.l634.
Full textAbstract:
Low- and high-density lipoproteins (LDL and HDL, respectively) stimulate alveolar type II cells to secrete surfactant. Increases in phosphoinositide hydrolysis, cytosolic Ca2+, and membrane-associated protein kinase C activity precede LDL- and HDL-stimulated secretion. We report three lines of evidence supporting the hypothesis that Gi mediates LDL- and HDL-stimulated surfactant secretion and signal transduction in type II cells. First, pertussis toxin (PTX) inhibited secretion stimulated by the apolipoprotein ligands for either the LDL receptor or the HDL binding protein. Second, PTX inhibited protein kinase C activity in cell membranes stimulated by LDL or HDL. Third, treatment of cell membranes with LDL or HDL inhibited PTX-catalyzed labeling of substrates corresponding in molecular mass to Gi alpha. These observations suggest that receptor-mediated activation of Gi is required for LDL- and HDL-stimulated secretion and that LDL and HDL activate Gi. These studies in type II cells are the first to support the hypothesis that Gi mediates the effects of LDL or HDL on important phenotype-specific functions of differentiated cells.
8
Enomoto, Mika, Hisashi Adachi, Yuji Hirai, Ako Fukami, Akira Satoh, Maki Otsuka, Shun-Ichi Kumagae, et al. "LDL-C/HDL-C Ratio Predicts Carotid Intima-Media Thickness Progression Better Than HDL-C or LDL-C Alone." Journal of Lipids 2011 (2011): 1–6. http://dx.doi.org/10.1155/2011/549137.
Full textAbstract:
High-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) are strong predictors of atherosclerosis. Statin-induced changes in the ratio of LDL-C to HDL-C (LDL-C/HDL-C) predicted atherosclerosis progression better than LDL-C or HDL-C alone. However, the best predictor of subclinical atherosclerosis remains unknown. Our objective was to investigate this issue by measuring changes in carotid intima-media thickness (IMT). A total of 1,920 subjects received health examinations in 1999, and were followed up in 2007. Changes in IMT (follow-up IMT/baselineIMT×100) were measured by ultrasonography. Our results showed that changes in IMT after eight years were significantly related to HDL-C (inversely,P<0.05) and to LDL-C/HDL-C ratio (P<0.05). When the LDL-C/HDL-C ratios were divided into quartiles, analysis of covariance showed that increases in the ratio were related to IMT progression (P<0.05). This prospective study demonstrated the LDL-C/HDL-C ratio is a better predictor of IMT progression than HDL-C or LDL-C alone.
9
Miida, Takashi, Yuichi Nakamura, Toru Mezaki, Osamu Hanyu, Seitaro Maruyama, Yoshinori Horikawa, Sachiko Izawa, Yukio Yamada, Hiroshi Matsui, and Masahiko Okada. "LDL-cholesterol and HDL-cholesterol concentrations decrease during the day." Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 39, no. 3 (May 1, 2002): 241–49. http://dx.doi.org/10.1258/0004563021901946.
Full textAbstract:
Background Homogenous assays for LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) are highly accurate, with little interference from triglyceride. Using these methods, we measured postprandial LDL-C and HDL-C. Earlier studies suggested a postprandial decrease in LDL-C. Methods To elucidate whether LDL-C and HDL-C decrease significantly during the day, we determined daily profiles of LDL-C and HDL-C using homogeneous assays in subjects with normal coronary arteries (N; n = 10), and subjects with coronary artery disease (CAD; n = 23). Results In both groups, LDL-C and HDL-C were significantly lower from after breakfast until midnight than they were before breakfast. The next morning, they returned to baseline levels. The mean reduction in LDL-C was 0·09--0·13 mmol/L in N and 0·05--0·20 mmol/L in CAD, while that in HDL-C was 0·02--0·06 mmol/L in N and 0·00--0·05 mmol/L in CAD. Conclusion LDL-C and HDL-C decrease significantly over the course of the day.
10
Karádi, I., L. Romics, P. Kempler, I. Balogh, I. Szilvási, and L. Littmann. "HDL protection against atherogenic LDL?" Basic Research in Cardiology 82, no. 6 (November 1987): 596–97. http://dx.doi.org/10.1007/bf01907230.
Full textDissertations / Theses on the topic "LDL/HDL"
1
Zerrad-Saadi, Amal. "Stress oxydant et LDL : mécanismes de l'effet protecteur des HDL." Paris 5, 2008. http://www.theses.fr/2008PA05P640.
Full textAbstract:
Le rôle antiathérogène des HDL est clairement établi. Cependant les mécanismes par lesquels les HDL exerceraient une activité antioxydante (AOX) contre une modification oxydative des LDL estent indéterminés. Notre premier objectif a été d'évaluer les relations entre les propriétés physicochimiques des sous-fractions d'HDL et leurs diverses actoivités antiathérogènes. Nous avons démontré que les HDL3, comparés aux HDL2, sont plus pauvres en sphingomyéline et plus riches en spingosine-1-phosphate. De plus, les HDL3 possèdent un rapport apolipoprotéine AI (apoAI) sur l'apolipoprotéine II, et des activités enzymatiques à propriétés anti-oxydatives, plus élevées. Nous avons également étudié les mécanismes impliqués dans l'activité AOX des HDL. Nos données suggèrent un mécanisme en deux étapes, (i) un transfert des hydropéroxydes de phospholipides (PLOOH) des LDL oxydées vers les HDL ; cette étape est influencée par la fluidité de la monocouche lipidique des HDL, et (ii) la réduction des PLOOH en PLOH principalement grâce à l'action de deux méthionines de l'apoAI. Ce travail souligne l'importance des hdl dans l'atténuation de l'athérogénécité potentielle des LDLThe capacité of HDL to protect LDL against oxidative stress is well established. However, mechanisms involved in such activity remain undetermined. Our firts aim was to assess the relationship between physicochemical properties of sub-fractions of LDL and their antiatherogenic in particular antioxidative (AOX) activities. We have demonstrated that HDL3 is depleted in spingomyelin and enriched in spingosine-1-phosphate as compared to HDL2. In addition, HDL3 displayed an elevated ratio of apolipoprotein AI (apoAI) to apoAII, and increased activities of HDL-associated enzymes with AOX properties. We have also studied mechanisms involved in the AOX activity of HDL Our data suggest a two-step mechanism involving transfer of phospholipids hydroperoxides (PLOOH) from oxidized LDL to HDL ; this step is influenced by the fluidity of the PL monolayer de HDL, and the reduction of PLOOH to redox-inactive PLOH largely through the action of two methionine residues of apoAI. This study emphasizes the importance of HDL in mitigating potential atherogenecity of LDL
2
Brindisi, Marie-Claude. "Relaxation vasculaire et HDL : rôle de la glycation et de l'oxydation des HDL sur la capacité de ces HDL à contrecarrer les effets inhibiteurs des LDL oxydées sur la vasorelaxation endothélium-dépendante." Thesis, Dijon, 2012. http://www.theses.fr/2012DIJOMU05.
Full textAbstract:
Contrairement aux HDL de sujets sains, les HDL de patients diabétiques ont perdu leur capacité à contrecarrer les effets inhibiteurs des LDL oxydées sur la vasorelaxation endothélium dépendante. Les mécanismes en cause ne sont pas connus. Or la glycation et l’oxydation sont deux phénomènes majeurs au cours du diabète. Nous avons donc étudié in vitro, le rôle de la glycation (associée ou non à une oxydation spontanée), et de l’oxydation d’HDL issues de sujets sains, sur leurs capacités à contrecarrer les effets inhibiteurs des LDL oxydées sur la vasorelaxation endothélium dépendante. Chaque condition a conduit au même constat: les HDL modifiées perdent leur pouvoir vasorelaxant en présence de LDL oxydées. En revanche, en l’absence de LDL oxydées, elles n’altèrent pas la vasorelaxation induite par l’acétylcholine. Ainsi les modifications structurelles des HDL (glycation, oxydation, ou les deux) induisent une perte de leur capacité à protéger l’endothélium du stress oxydatif, plutôt qu’un effet délétère direct sur l’endothélium. Un des mécanismes majeur impliqué dans ce phénomène est probablement l’absence de fixation de ces HDL modifiées à leur récepteur SR-BI. Elles ne pourraient plus alors s’opposer au niveau des cavéoles aux effets délétères des LDL oxydées, et ne favoriseraient plus la production de NO. Mais si aussi bien la glycation que l’oxydation des HDL entraînent ces effets néfastes, il semblerait qu’en condition physiopathologique (oxydation spontanée des HDL glyquées), l’oxydation ne majore pas cette perte de capacité des HDL à contrecarrer les effets inhibiteurs des LDL oxydées sur la vasorelaxationContrary to HDL from normolipidaemic and normoglycaemic subjects, HDL from diabetic patients have lost their capacity to reverse the inhibition of vasorelaxation induced by oxidized LDL. Mechanisms involved are unknown. The glycation and oxidation of HDL are two major phenomena in diabetes mellitus. The aim of this work was to study in vitro the role of glycation (with or without spontaneous oxidation) and oxidation of HDL, on their capacity to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation. Each state showed the same result, modified HDL lost their vasorelaxing power in stress conditions (with oxidized LDL). Nevertheless, modified HDL alone (without oxidized LDL) did not alter vasorelaxation induced by acetylcholine, after noradrenaline-induced vasoconstriction. Thus, modifications of HDL induce a loss of the ability to protect vessels from oxidative stress rather than have a direct deleterious effect on the vessel. One of the major mechanisms involved in this phenomenon is probably the loss of SR-BI binding of these modified HDL, that could lead to the inability of HDL to protect caveolae from deleterious effects induced by oxidized LDL and could not preserve NO production. However, though glycation, like oxidation of HDL, leads to these deleterious effects, it would seem that during physiopathological conditions, with the spontaneous oxidation of glycated HDL, oxidation does not aggravate the loss of the capacity of diabetic HDL to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation
3
Andersson, Mari. "Har kost och statiner var för sig eller i kombination någon effekt på LDL och HDL?" Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-82401.
Full textAbstract:
Bakgrund: Kolesterol är en viktig byggsten i våra celler. Kolesterol stabiliserar cellmembranen och används bland annat till syntesen av östrogen, testosteron, kortisol och vitamin D samt för att bilda gallsyror. Kolesterol syntetiseras i levern men tas även upp via kosten. Kolesterol transporteras i blodet med hjälp av olika lipoproteiner som t. ex. low-density lipoprotein (LDL) och high-density lipoprotein (HDL).Höga värden av LDL och låga värden av HDL är kopplade till en ökad risk att drabbas av ateroskleros som i sin tur ökar risken att drabbas av hjärt-och kärlsjukdomar som t. ex. hjärtinfarkt. Syfte: Syftet med arbetet var att studera hur plasmakoncentrationen av LDL och HDL förändras vid olika dieter i kombination med statiner eller utan statiner samt se hur koncentrationerna förändras vid läkemdelsbehandling med statiner som monoterapi eller i kombination med ezetimib. Metod: Detta arbete är en litteraturstudie baserad på sju olika randomiserade kontrollerade studier sökta från databasen PubMed. I tre av studierna utvärderas kostens roll att sänka kolesterolet. I två studier behandlades patienter med atorvastatin som monoterapi eller med kombination av ezetimib. Två studier utvärderade om simvastatin ska tas på morgon eller kväll samt om simvastatin skall tas i kombination med LCHF-kost jämfört med simvastatin plus ezetimib i kombination med LCHF-kost. Resultat: Resultaten visar att viktreducering och kostomläggning har stor betydelse vid förhöjdanivåer av LDL samt vid låga nivåer av HDL. Resultaten visar även att statiner i kombination med ezetimib har störst effekt att sänka nivåerna av LDL och öka HDL-nivåerna. Av resultaten framgår också att kontrollerad frisättning av simvastatin har likvärdig effekt oavsett om de adminstreras morgon eller kväll. Slutsats: Denna litteraturstudie har visat att viktreducering och kost är ett bra och säkert tillvägagångssätt att få positiva effekter på HDL- och LDL-koncentrationerna. Statiner är förstahandspreparat vid blodfettsrubbningar och vid förhöjda kolesterolvärden och har en god effekt på kolesterol-nivåerna. För bästa resultat bör kost med låg andel kolhydrater kombineras med statiner och ezetimib.Background: Cholesterol is an important part in our cells. Cholesterol stabilize cell membranes and is needed for the synthesis of estrogen, testosterone, cortisol, vitamin D and in the formation of bile acid. Cholesterol is synthesized in the liver but the body also absorbs cholesterol from the diet. The transport of cholesterol in the blood is taken care of by LDL and HDL. When the levels of LDL are increased and HDL are decreased there is an increased risk of developing atherosclerosis and cardiovascular diseases which are the main cause of death in the western countries. Purpose: One of three different purposes of this presented study was to evaluate if the levels of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were changed when following different diets. The second purpose was to study the change in levels of LDL and HDL change after treatment with statins as monotherapy or in combination with ezetimibe. The third part of this study was to see how LDL and HDL were changed when different diets were combined with statins. Method: This work was a literature study based on seven different randomized controlled trials that were found in the database PubMed. Three of the studies evaluated the role of the different diets when aiming at reducing the cholesterol levels. In two of the studies patients were either treated with atorvastatin as monotherapy or with atorvastatin plus ezetimib. The last two studies evaluated the use of simvastatin in combination with LCHF-diet as compared to the use of simvastatin plus ezetimib which were used in combination with a LCHF-diet. Results: The results showed that weight reduction and the choice of a specific diet are important factors when aiming at a decrease in levels of LDL and an increase in levels of HDL. Moreover, results obtained also suggested that statins, when used in combination with ezetimibe, gave the largest effect and was found to decrease levels of LDL and increase levels of HDL. According to the results, it may be concluded that the controlled release of simvastatin has an equivalent effect on these levels regardless if administered in the morning or in the evening. Conclusion: The results obtained in this work suggest that weight reduction and eating according to a diet that consists of a low proportion of carbohydrates may be a good and safe approach to reduce the levels of LDL and increase the levels of HDL. Statins can be considered to be the first alternative to treat dyslipidemia and should be used at elevated levels of cholesterol. To achieve the best result, an analysis of the selected literature in this work, suggest that a low-carbohydrate diet should be combined with the use of statins and ezetimibe.
4
Marangoni, Adriane Bueno. "Baixa suplementação de azeite de oliva reduz triaciglicerois e características lipídicas e oxidativas associadas à lipoproteína de baixa densidade em indivíduos com risco cardiovascular intermediário e alto." Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/6/6138/tde-21102014-100904/.
Full textAbstract:
Introdução: A doença cardiovascular é a principal causa de morbimortalidade precoce em todo o mundo, e responde por grande parte dos gastos dos recursos destinados aos programas de políticas públicas. Neste contexto, a dieta representa uma importante ferramenta na redução dos fatores de risco cardiovasculares. Tendo em vista que inúmeros estudos mostram que o consumo de ômega 9 ou alimento fonte modifica positivamente diversos fatores de risco cardiovascular clássicos, se torna importante avaliar seu efeito sobre propriedades físico-químicas da LDL e da HDL, marcadores cardiometabólicos e oxidativos em indivíduos brasileiros com diferentes níveis de risco cardiovascular. Objetivo: Avaliar o efeito do consumo de azeite de oliva sobre parâmetros cardiometabólicos clássicos e novos em indivíduos com diferentes níveis de risco cardiovascular. Métodos: O estudo foi do tipo clínico prospectivo, aleatorizado, placebo controlado, duplo cego baseado em intervenção nutricional. Indivíduos de ambos os sexos, distribuídos em grupos azeite de oliva (AO) e placebo (PL) receberam durante 8 semanas 3 g/d de azeite de oliva ou placebo. Todos os indivíduos foram classificados quanto ao risco cardiovascular, seguindo os critérios estabelecidos pelo Escore de Risco de Framingham (ERF). Nos momentos basal, T=4S e T=8S foram determinados o perfil clínico, antecedentes familiares de doenças, pressão arterial, consumo alimentar e nível de atividade física. A partir do plasma ou soro, obtidos após 12 h de jejum, foram determinados o perfil lipídico, as apolipoproteínas, o tamanho da HDL e da LDL, o conteúdo de LDL(-) e de NEFAS e atividade da paraoxonase. A aderência à intervenção foi monitorada por meios diretos (marcadores bioquímicos) e indiretos (registro de intercorrências). Resultados: O azeite de oliva foi efetivo em reduzir concentração de triacilglicerois dos indivíduos em alto risco cardiovascular (p=0,023 no T=4S e p=0,049 no T=8S) e a de LDL-C dos indivíduos com risco cardiovascular intermediário (p=0,045 no T=8S) no atual estudo. Observou-se também redução significativa na LDL(-), quando a amostra foi estratificada pelo ERF. Demais parâmetros permaneceram inalterados em função do tempo da intervenção e do ERF. Conclusão: Baixa suplementação (3 g/d) de azeite de oliva promoveu redução dos triacilglicerois, LDL-C e da LDL(-). Portanto, recomenda-se a incorporação de azeite de oliva na dieta brasileira ainda que em baixas doses. Sugere-se também que estudos adicionais usando doses maiores sejam realizados no sentido de identificar potenciais benefícios cardioprotetores adicionais associados ao consumo de azeite de oliva.Introduction: Cardiovascular disease is the leading cause of premature morbidity and mortality worldwide, and accounts for a large part of the costs of resources devoted to public policy programs. In this context, the diet is an important tool in managing and reducing the risk of cardiovascular disease. Given that numerous studies show that consumption of omega 9 or food source changes positively several classical cardiovascular risk factors, it becomes important to evaluate its effect on physicochemical properties of LDL and HDL, cardiometabolic and oxidative markers in Brazilian individuals with different levels of cardiovascular risk. Objective: This study aimed to evaluate the effect of consuming olive oil on classical and new cardiometabolic properties in individuals with different levels of cardiovascular risk. Methods: It was a clinical, prospective, randomized, placebo controlled, double blind study based on nutritional intervention. Individuals of both sexes, divided into groups olive oil (AO) and placebo (PL) for 8 weeks received 3 g/d of olive oil or placebo. All subjects were classified for cardiovascular risk following the criteria established by the Framingham Risk Score (FRS). At baseline period, T = 4W and T = 8W the clinical profile, the family history of diseases, blood pressure, food consumption and physical activity level were determined. From plasma or serum obtained after 12 h of fasting lipid profile, apolipoproteins, the size of LDL and HDL, LDL (-) and NEFAS content, and activity of paraoxonase were determined. Adherence to the intervention was monitored by direct means (biochemical markers) and indirect (register of complications). Results: The olive oil was effective in reducing the concentration of triacylglycerol of individuals at high cardiovascular risk (p = 0.023 at T=4W and p=0.049 at T=8W) and LDL-C in individuals with intermediate cardiovascular risk (p=0.045 at T=8W) in the current study. It was also observed a significant reduction in LDL (-) when the sample was divided by the FRS. However, changes in other parameters were not detected when comparing the intervention group and the placebo group. Conclusion: Even at low dosage, olive oil has proved to be beneficial in reducing triglycerides, LDL-C and LDL (-).It is therefore recommended the incorporation of olive oil in the Brazilian diet even in low doses. It is suggested that future studies to use higher doses in order to check additional benefits associated with olive oil consumption.
5
Santos, Andreza Oliveira dos [UNIFESP]. "Relação entre os títulos de anticorpos anti LDLox e marcadores do risco cardiovascular." Universidade Federal de São Paulo (UNIFESP), 2008. http://repositorio.unifesp.br/handle/11600/10030.
Full textAbstract:
Made available in DSpace on 2015-07-22T20:50:43Z (GMT). No. of bitstreams: 0
Previous issue date: 2008-11-26Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Objetivos: As lipoproteínas oxidadas e os anticorpos anti-LDL oxidada (anti-LDLox) têm sido detectados no plasma e em lesões ateroscleróticas em humanos. No entanto, o papel destes autoanticorpos na proteção vascular ou na patogênese das síndromes coronarianas agudas (SCA) permanece não elucidado. Nós examinamos a relação entre os títulos de IgG humana anti-LDLox com marcadores de risco para a doença cardiovascular. Métodos: Títulos de autoanticorpos anti-LDLox foram mensurados em indivíduos portadores de hipertensão arterial em estágio 1 (n=94), sem outros fatores de risco, e em indivíduos com síndrome metabólica após recente síndrome coronariana aguda (n=116). Os autoanticorpos contra a LDL oxidada pelo cobre foram avaliados por ELISA. Resultados: pacientes com hipertensão arterial apresentaram menor índice de massa corpórea e circunferência abdominal, maiores níveis de pressão arterial sistólica e diastólica quando comparados aos portadores de SCA (p<0,001). O HDL-C e a Apo A1 foram maiores, enquanto os triglicérides e a Apo B foram menores nos pacientes do grupo hipertensão em estágio 1 (p<0,0001). Os títulos de anticorpos anti-LDLox foram maiores no grupo hipertensão comparados aos do grupo SCA, e os hipertensos do primeiro grupo apresentaram níveis de PCR menores do que indivíduos com SCA (p<0,0001). A análise conjunta de ambos os grupos mostrou, em análise univariada, significante correlação inversa para a PCR (r=-0,284), IMC (r=-0,256), circumferência abdominal (r=-0,368), apo B (r=-0,191) e glicemia (r=-0,303) e correlações positivas entre pressão arterial sistólica e diastólica (r=0,319 e r=0,167, respectivamente), HDL-C e Apo A1 (r=0,224 e r=0,257, respectivamente), com os títulos de anticorpos anti-LDLox (p<0,02). Regressão linear múltipla mostrou que a PCRas, glicemia e circunferência abdominal permaneceram independente e negativamente associados com os títulos de anticorpos anti-LDLox. Conclusões: nossos resultados sugerem que os títulos baixos de anticorpos circulantes anti-LDLox possam estar associados com maior risco cardiovascular.
Objectives: Oxidized lipoproteins and antibodies anti-oxidized LDL (anti-oxLDL) have been detected in human plasma and in atherosclerotic lesions. However, the role of these autoantibodies in the maintenance of health or in the pathogenesis of acute coronary syndromes (ACS) remains unclear. We examined the relationship of human IgG antibodies anti- ox LDL with cardiovascular disease risk markers. Methods: Titers of human anti-oxLDL were measured in hypertensive subjects in stage 1 (n=94) without other risk factors, and in individuals with metabolic syndrome after recent acute coronary syndrome (n=116). Autoantibodies against copper ion oxidized LDL were measured by ELISA. Results: Hipertensive patients presented lower BMI, waist circunference, higher blood pressure levels than those with ACS (p<0.001). HDL-C and Apo A1 were higher, whereas triglycerides and Apo B were lower in those with hypertension stage 1 (p<0.0001). Anti-oxLDL titers were higher in hypertensive patients compared to those with acute coronary syndromes, and hypertensive patients presented lower hs-CRP than those with ACS (p<0.0001). Taken into account both populations, univariate analysis showed small, but significant inverse correlations between the hs-CRP (r=-0.284), BMI (r=-0.256), waist circunference (r=-0.368), apo B (r= -0.191), and blood glucose (r= - 0.303) and positive correlations between systolic and diastolic blood pressure (r=0.319 and r=0.167, respectively), HDL-C and Apo A1 (r=0.224 and r=0.257, respectively), with anti-ox LDL titers (p<0.02). After multiple linear regression, hs-CRP, fasting glycemia and waist circunference remained independently associated with anti-oxLDL. Conclusions: Our results suggest that low titers of circulating anti-oxLDL antibodies may be associated with increased cardiovascular risk.
TEDE
BV UNIFESP: Teses e dissertações
6
Spessatto, Débora. "Associação dos níveis de HbA1c com colesterol LDL e colesterol LDL oxidado em indivíduos não-diabéticos." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2011. http://hdl.handle.net/10183/39649.
Full textAbstract:
Introdução: O Diabetes mellitus (DM) está associado a complicações crônicas micro e macrovasculares. A medida da hemoglobina glicada (HbA1c) avalia o grau do controle glicêmico em pacientes diabéticos e seus níveis são capazes de prognosticar o risco de desenvolvimento dessas complicações. Entre as origens das complicações causadas pela hiperglicemia, há a hipótese dos produtos finais de glicação avançada (AGEs) e do estresse oxidativo. A reação de glicação não enzimática das proteínas também está relacionada com as complicações diabéticas e é responsável pela formação da HbA1c. Entretanto, tem sido demonstrado um aumento dessa glicação em pacientes não diabéticos. Um dos prováveis mecanismos para esse aumento é a peroxidação lipídica, com conseqüente aumento nos níveis de malondialdeído (MDA) que modifica a apolipoproteína B (APO B) do colesterol de baixa densidade (LDL). A modificação oxidativa do LDL confere propriedades específicas pró-aterogênicas. A presença do LDL oxidado e o aumento da tendência do LDL à peroxidação lipídica, podem contribuir para o aumento dos níveis de HbA1c. Objetivo: Verificar a associação entre os níveis de HbA1c com o Colesterol LDL e LDL oxidado em Indivíduos não-diabéticos. Métodos: Foi realizado um estudo transversal observacional, no qual um total de 196 indivíduos, classificados como não-diabéticos, foram analisados e divididos em três grupos, conforme os valores de HbA1c e glicemia de jejum (GJ): Grupo 1 (n =64) - HbA1c <5,7% e GJ <100 mg/dL; Grupo 2 (n =69) - HbA1c ≥5,7 e ≤6,4% e GJ <100 mg/dL; Grupo 3 (n =63) - HbA1c ≥5,7 e ≤6,4% e GJ ≥100 e <126mg/dL. Amostras de sangue total e soro foram coletadas. O LDL oxidado foi medido por método imunoensaio enzimático (Mercodia ®), ApoB dosada por imunoturbidimentria, a relação Colesterol LDL(oxi)/Colesterol-HDL foi estimada, além das outras dosagens bioquímicas do perfil lipídico. Esses testes foram comparados e analisados entre os três diferentes grupos. Resultados: Houve diferença significativa nos níveis de LDL(oxi) (p< 0,001), Apo B (p= 0,026) e razão LDL(oxi)/HDL (p< 0,001) entre os três grupos. Os valores de HbA1c apresentaram correlação positiva com os valores de LDL (oxi) (r =0,431; p <0,001), LDL (r =0,148; p =0,039), Col Não-HDL (r =0,192; p =0,007) e Apo B (r =0,171; p <0,001). Estas associações positivas permaneceram significativas, mesmo após ajuste, por análise de regressão linear múltipla para as variáveis álcool, medicamentos, índice de massa corporal (IMC) e idade. Também apresentaram correlações positivas com os valores de HbA1c: razão LDL (oxi)/HDL (r =0,422; p <0,001), CT (r =0,142; p =0,048), triglicerídios (r =0,155; p =0,030) e IMC (r =0,263; p <0,001). Conclusão: Nosso estudo demonstrou associação dos níveis de HbA1c com as partículas lipídicas aterogênicas LDL, Apo B, colesterol não HDL e LDL (oxi). Os níveis de LDL, principalmente LDL (oxi), estão significativamente associados com os níveis de HbA1c e glicose, mesmo em indivíduos não-diabéticos. Os indivíduos classificados com alto risco de desenvolver DM ou DCV apresentam valores mais elevados de partículas de LDL oxidadas. Nossos dados sugerem que a presença de LDL (oxi) está relacionada com a glicação e ao aumento dos níveis sanguíneos de HbA1c em indivíduos não diabéticos.Background: Diabetes mellitus (DM) is associated with chronic microvascular and macrovascular complications. The measurement of glycated hemoglobin (HbA1c) assesses the degree of glycemic control in diabetics patients and their levels are able to predict the risk of developing these complications. The formation of advanced glycation and products (AGEs) and oxidative stress are some of the hypothesis described to explain the diabetic complications. The reaction of nonenzymatic glycation of proteins is also related to these complications and is responsible for the formation of HbA1c. However, it has been shown an increase in glycation in nondiabetic patients, which is maybe due to lipid peroxidation, consequently, the levels of malondialdehyde (MDA) increase and there is modifications in the apolipoprotein B (apoB) of low-density cholesterol (LDL). The oxidative modification of LDL confers specific proatherogenic properties. The presence of oxidized LDL and an increased tendency to LDL peroxidation contribute to increased levels of HbA1c in diabetic patients. Objective: To investigate the association between HbA1c levels and the levels of LDL cholesterol and oxidized LDL in subjects without diabetes. Methods: We conducted an observational cross-sectional study in which a total of 196 individuals, classified as non-diabetics, were analyzed and divided into three groups according to the values of HbA1c and fasting plasma glucose (FPG): Group 1 (n = 64) - HbA1c <5.7% and FPG <100 mg / dL, Group 2 (n = 69) - HbA1c ≥ 5.7 and ≤ 6.4% and FPG <100 mg / dL, Group 3 (n = 63) - HbA1c ≥ 5.7 and ≤ 6.4% and FPG ≥ 100 and <126mg/dL. Samples of whole blood and serum were collected. Oxidized LDL was measured by enzyme immunoassay method (Mercodia ®), ApoB was measured by imunoturbidimentria and the ratio LDL cholesterol (oxi) / HDL-cholesterol was estimated. Other biochemical measurements of lipid profile were also carried out. Results: There were significant differences in LDL (oxi) (p <0.001), Apo B (p = 0.026), and ratio LDL (oxi) / HDL (p <0.001) between the three groups. HbA1c values showed positive association with LDL (oxi) (r = 0.431, p <0.001), LDL (r = 0.148, p = 0.039), non-HDL Col (r = 0.192, p = 0.007) and Apo B (r = 0.171, p <0.001). These positive associations remained significant even after adjustment for multiple linear regression analysis for variables such as alcohol, drugs, BMI and age. The ratio LDL (oxi) / HDL (r = 0.422, p <0.001), CT (r = 0.142, p = 0.048), triglycerides (r = 0.155, p = 0.030) and BMI (r = 0.263, p <0.001) also showed positive correlations with HbA1c values. Conclusions: Our study demonstrated that there is association between HbA1c levels and the atherogenic lipid particles LDL, Apo B, non-HDL cholesterol and LDL (oxi). LDL levels, especially LDL (oxi), are significantly associated with HbA1c and glucose levels, even in non-diabetics. Individuals classified with high risk of developing diabetes or CVD have higher levels of oxidized LDL particles. Our data suggest that the presence of LDL (oxi) is related to glycation and increased blood levels of HbA1c in nondiabetic individuals.
7
Schofield, Jonathan. "HDL functionality and lipoprotein quality in diabetes mellitus." Thesis, University of Manchester, 2017. https://www.research.manchester.ac.uk/portal/en/theses/hdl-functionality-and-lipoprotein-quality-in-diabetes-mellitus(a164e8f2-692a-4ac8-aa29-5e8f31d3c217).html.
Full textAbstract:
Background & Aims: The 'high-density lipoprotein (HDL) hypothesis', that therapeutic interventions directed at raising HDL cholesterol might translate into improved cardiovascular outcomes, has been confounded by recent reports from genetic and pharmacological studies. HDL functionality may be more important than cholesterol cargo. HDL cholesterol levels are normal or even high in Type 1 Diabetes (T1DM) but do not seem to protect against atherosclerosis as might be expected; this thesis aims to offer new insight into HDL functionality through examination of these patients. This thesis also aims to improve understanding of the qualitative changes in lipoproteins associated with diabetes and increased cardiovascular morbidity, with emphasis on atherogenic modifications of apolipoprotein B and sphingolipids, and consideration of the relationship between these changes, novel and established biomarkers, and macrovascular and microvascular diabetic complications. Materials & Methods: Patients with Type 1 (n = 91) and Type 2 (n = 40) Diabetes Mellitus and healthy volunteers (n = 104) attended for fasting blood tests, urinalysis, and examination including cardiac computed tomography, carotid doppler studies and assessments of nerve function. In vitro studies of lipoprotein modification used pooled human plasma. Results: Lipoprotein glycation represents an atherogenic modification. In vitro glycation occurs more readily in the presence of physiological concentrations of copper. HDL and copper-selective chelation with triethylenetetramine prevents glycation. Glycated apolipoprotein B, oxidized LDL and small-dense LDL levels were significantly higher in T1DM; HDL cholesterol levels were also significantly higher, but with altered apolipoprotein distribution, and significantly lower cholesterol efflux capacity and PON1 activity than in healthy controls. Significant changes were also observed in cystatin C, advanced glycation end-products, leucine-rich alpha-2-glycoprotein, lipoprotein-associated phospholipase A2, a variety of inflammatory markers, and sphingolipid and ceramide profiles. Discussion: Cardiovascular disease is the leading cause of death and disability in diabetes. Patients with diabetes show qualitative and kinetic lipoprotein abnormalities, and any cardiovascular benefit associated with intensive glucose lowering may be related to effects on lipoprotein metabolism rather than directly through altered glycaemia. The apparently relatively undisturbed lipid profile observed in many patients with diabetes hides major atherogenic changes and altered HDL functionality, which may be at least partially responsible for the persistent increased risk of cardiovascular disease in patients with diabetes. HDL-based therapy remains a largely unfulfilled promise, but there may be a role for copper-selective chelation and more aggressive low-density lipoprotein lowering in the reduction of diabetic complications.
8
Freitas, Maria Camila Pruper de. "Papel do ômega-3 nas características físico-químicas da HDL e LDL e possível associação com medidas Z-scan em indivíduos adultos." Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/6/6138/tde-17092015-094133/.
Full textAbstract:
Introdução: O aumento na prevalência das doenças cardiovasculares alerta para a necessidade de estratégias eficazes e de baixo custo como medidas preventivas na redução dos fatores de risco, morbidades e óbitos decorrentes de eventos coronarianos. As modificações no estilo de vida são as primeiras alternativas a serem adotadas. Nesse contexto, a dieta ocupa lugar de destaque e os benefícios dos ácidos graxos poli-insaturados ômega-3 na saúde cardiovascular são amplamente reconhecidos. As doenças cardiovasculares são influenciadas por diversos fatores de risco e o desequilíbrio na concentração plasmática das lipoproteínas é um fator de risco independente no desenvolvimento da doença cardiovascular aterosclerótica. Entretanto, há evidências de que as subfrações lipoproteicas podem influenciar o risco cardiovascular de maneira diferenciada, dependendo das características físico-químicas e funcionalidade de cada partícula. O desenvolvimento de novas técnicas, capazes de identificar esses parâmetros, tem sido foco de grande interesse científico. Objetivo: Avaliar o papel do ômega-3 sobre as características físico-químicas da LDL e HDL e possível associação entre medidas Z-scan e marcadores cardiometabólicos em indivíduos adultos. Metodologia: A partir de uma subamostra do estudo CARDIONUTRI (estudo clínico, randomizado, controlado e duplo cego com seguimento de 8 semanas) foram selecionados 36 indivíduos do Grupo Ômega-3 (3,0g/dia de óleo de peixe - 1,11g de EPA + 0,69g de DHA) e 27 do Grupo Placebo (3,0g/dia de óleo mineral). Foram monitorados o perfil clínico, antecedentes familiares, consumo alimentar, atividade física e antropometria. Amostras de sangue foram coletadas após 12 horas de jejum para avaliação das concentrações plasmáticas de CT, TAG, HDL-C, LDL-C, APOAI, APOB, PON1 e glicose. O tamanho da HDL e LDL foi analisado pelo método padronizado Lipoprint®. O conteúdo de LDL(-) foi determinado por ELISA. As medidas Z-scan foram determinadas por meio da difusividade térmica e absorção linear da LDL (1,0 mg/dL de proteína), isolada por ultracentrifugação. Todos as variáveis do estudo foram avaliadas no momento basal e após 8 semanas de intervenção. A adesão à intervenção foi monitorada pela contagem de cápsulas e percentual dos ácidos graxos plasmáticos. Para avaliar a associação das medidas Z-Scan aos marcadores cardiometabólicos, os dados obtidos no momento basal foram submetidos à Análise de Componentes Principais. Resultados: A idade média dos participantes do estudo foi de 51,5 (10,5) anos. A suplementação com ômega-3 promoveu redução significativa de CT, TAG, não-HDL, HDLPEQUENA e LDL(-), além de aumento significativo de HDL-C e HDLGRANDE. O ômega-3 foi mais eficaz na redução dos TAG (29,2 por cento ) quando comparado ao placebo (2,9 por cento ). O Grupo Ômega-3 apresentou aumento de HDLGRANDE (16,9 por cento ) e redução de HDLPEQUENA (-16,3 por cento ) ao final da intervenção, com diferença significativa quando comparado ao Grupo Placebo que apresentou redução de HDLGRANDE (-4,8 por cento ) e aumento de HDLPEQUENA (17,7 por cento ). Não foram observadas diferenças nas medidas Z-scan após a intervenção, porém as medidas se associaram positivamente a Componentes Principais com padrões cardioprotetores da amostra e negativamente a padrões aterogênicos. Conclusão: O ômega-3 demonstrou efeito positivo no perfil lipídico e propriedades aterogênicas das subfrações lipoproteicas. A suplementação com ômega-3 não modificou as medidas Z-scan, no entanto, a técnica demonstrou ser uma ferramenta capaz de se associar a padrões aterogênicos e antiaterogênicos monitorados no presente estudoIntroduction: The increased of cardiovascular disease prevalence draws attention to the need to adopt effective and inexpensive strategies as preventive measures to reduce risk factors, morbidity and deaths from coronary events. Lifestyle modification is indicated as first alternative to be adopted. In this context the diet stands out and omega-3 polyunsaturated fatty acids benefits on cardiovascular health are largely recognized. Cardiovascular diseases are influenced by several risk factors and the plasma imbalance lipoprotein is considered a crucial independent risk factor. However, there is evidence of the influence of lipoprotein subfractions in cardiovascular risk, based on the physicochemical characteristics of these particles. The development of new techniques able to identify those parameters has been the focus of great scientific interest. Objective: To evaluate the role of omega-3 on HDL and LDL physicochemical characteristics and possible association between Z-scan measurements and cardiometabolic markers in adults. Methods: From a subsample of the study CARDIONUTRI (clinical, randomized, controlled, double blind study with 8-week follow-up) were selected 36 individuals from the Omega-3 Group (3.0g/day of fish oil - 1,11g EPA + 0.69g DHA) and 27 individuals from the Placebo Group (3.0g/day of mineral oil). The clinical profile, family history, dietary intake, physical activity and anthropometry were monitored. Blood samples were collected after 12 hours of fasting to evaluate plasma concentrations of TC, TAG, HDL-C, LDL-C, APOAI, APOB, PON1 and glucose. The HDL and LDL size was analyzed by the standard method Lipoprint®. The levels of LDL (-) was determined by ELISA. The Z-scan measurements were determined by thermal diffusivity and linear absorption of LDL (1.0 mg / dL protein) isolated by ultracentrifugation. All study variables were evaluated at baseline and after 8 weeks of intervention. The intervention accession was monitored by capsule count and percentage of plasma fatty acids. To evaluate the association of the Z-Scan measurements to cardiometabolic markers, the data collected at baseline were subjected to Principal Component Analysis. Results: The average age of individuals were 51.5 (10.5) years. The omega-3 supplementation promoted a significant decreased of TC, TAG, non-HDL, small HDL and LDL(-), and significantly increased HDL-C and large HDL. The omega-3 was more effective in reducing the TAG (29.2 per cent ) when compared to placebo (2.9 per cent ). The Omega-3 Group increased large HDL (16.9 per cent ) and decreased small HDL (-16.3 per cent ) after the intervention, with significant difference when compared to the Placebo Group that decreased large HDL (-4.8 per cent ) and increased small HDL (17.7 per cent ). There were no differences in Z-scan measurements with the interventions, but were observed positively associated the Z-scan measurements with the anti-atherogenic sample patterns and negatively associated with atherogenic sample patterns when the sample was standardized from the Principal Components Analysis. Conclusion: The omega-3 demonstrated positive effect on the lipid profile and atherogenic lipoprotein subfractions. Supplementation with omega-3 did not modify the Z-scan measurements, however, the technique proved to be a tool that can be associated with atherogenic and anti-atherogenic sample patterns monitored in this study.
9
Karlsson, Helen. "Lipoproteomics : A New Approach to the Identification and Characterization of Proteins in LDL and HDL." Doctoral thesis, Linköping : Univ, 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-8527.
Full text
10
Yadav, Rahul. "HDL functionality and LDL quality : the influence of obesity, obstructive sleep apnoea and pharmacological intervention." Thesis, University of Manchester, 2013. https://www.research.manchester.ac.uk/portal/en/theses/hdl-functionality-and-ldl-quality-the-influence-of-obesity-obstructive-sleep-apnoea-and-pharmacological-intervention(60e83156-3d19-4ccb-999c-f57ac5c6ca46).html.
Full textAbstract:
Aims: LDL oxidation plays an important role in the initiation and progression of atherosclerosis. HDL impedes oxidation, glycation and glycoxidation in vitro and there is evidence to suggest paraoxonase-1 (PON1) plays an important role in this. 1. In patients with dyslipidaemia treated with statins, I assessed the relationship of serum PON1 activity with in vitro HDL antioxidant capacity, susceptibility of LDL to oxidation and the protection offered by HDL. 2. I studied the effect of the presence and severity of obstructive sleep apnoea (OSA) in morbidly obese patients on HDL anti-oxidant and anti-inflammatory functions. 3. I investigated the influence of extended release niacin/ laropiprant (ERN/LRP) versus placebo in patients who had persistent dyslipidaemia despite receiving high doses of potent statins. I assessed the effect of ERN/LRP on mediators of vascular inflammation and HDL's in vitro anti-oxidant function. Methods: 1. LDL isolated from dyslipidemic patients was incubated with and without HDL, in the presence of Cu2+. Similarly isolated HDL was incubated alone. Lipid peroxides (LPO) generated over 3 hours were measured. Patients were divided into 2 groups based on median serum PON1 activity. 2. 41 morbidly obese patients were divided into two groups based on the presence or absence of OSA ("OSA" and "no OSA" group) or on severity of OSA (high or low apnoea-hypoapnoea index (AHI) groups). I studied HDL's ability to protect itself from in vitro oxidation and measured serum PON1 activity, tumor necrosis factor alpha (TNFalpha) and intercellular adhesion molecule 1 (ICAM1). 3. This was a randomised double blind cross over trial, where I studied the effect of ERN/LRP compared to placebo in 27 patients who had high LDL-C inspite of maximum tolerated doses of statins. I measured lipid profile, apolipoproteins, cholesteryl ester transport protein (CETP) activity, paraoxonase 1 activity (PON1), oxidised LDL (oxLDL) and related mediators of vascular inflammation. I also examined the capacity of HDL to protect LDL from in vitro oxidation. Results and conclusion: 1. In statin treated dyslipidemic patients the capacity of HDL to protect itself and LDL from oxidation in vitro is significantly better in individuals with higher serum PON1 activity. 2. The capacity of HDL to protect itself from in vitro oxidation in morbidly obese patients is reduced with onset and severity of OSA. The differences in TNFalpha and ICAM1 levels may suggest endothelial dysfunction due to OSA. Oxidative damage of PON1 attributable to OSA could be a mechanism for HDL and endothelial dysfunction. 3. Treatment with ERN/LRP resulted in a significant improvement in HDL-C but did not affect HDL's in vitro anti-oxidant function in patients who had persistent dyslipidaemia despite high doses of potent statins. For the first time I have shown that ERN/LRP reduces mediators of vascular inflammation.
Books on the topic "LDL/HDL"
1
S, Pagano Irwin, and Strait Nathan B, eds. HDL and LDL cholesterol physiology and clinical significance. Hauppauge, NY: Nova Science Publishers, 2009.
Find full text
2
Gotō, Yūichirō. Global perspectives in lipid management: Regulating LDL-cholesterol, HDL-cholesterol, and triglycerides : their role in primary prevention of CHD. London: Royal Society of Medicine Press, 1998.
Find full text
3
Johnston, Philip. A study regarding the stability of peroxynitrite and its ability to oxidatively modify the protein moities of HDL and LDL cholesterol. [S.l: The Author], 1996.
Find full text
4
Turun yliopisto. Cardiorespiratory Research Unit. and Turun yliopisto. Dept. of Medicine., eds. Factors influencing tracking of serum lipid values in children and young adults: A 9-year follow-up study. Turku: Turun Yliopisto, 1991.
Find full text
5
M, Gotto Antonio, and Gotō Yūichirō 1922-, eds. Global perspectives in lipid management: Regulating LDL-cholesterol, HDL-cholesterol and triglycerides : their role in the primary prevention of CHD : proceedings of a symposium sponsored by Parke-Davis Pharmaceuticals held in London, UK, 9-10 October 1997. London: Royal Society of Medicine Press, 1998.
Find full text
6
1924-, Scanu Angelo M., ed. Lipoprotein (a). San Diego: Academic Press, 1990.
Find full text
7
Wiklund, Olov, and Jan Borén. Pathogenesis of atherosclerosis: lipid metabolism. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755777.003.0011.
Full textAbstract:
Lipids are carried in plasma as microparticles, lipoproteins, composed of a core of hydrophobic lipids and a surface of amphipathic lipids. In addition, the particles carry proteins (i.e. apolipoproteins). The proteins have key functions in the metabolism as receptor ligands, enzymes or activators. Lipoproteins are classified based on density into: chylomicrons, VLDL, IDL, LDL, and HDL. Retention of apoB-containing lipoproteins (LDL, IDL, and VLDL) in the arterial intima is the initiating event in the development of atherosclerosis. Retention is mediated by binding of apoB to structural proteoglycans in the intima. Increased plasma concentration of apoB-containing lipoproteins is the main risk factor for atherosclerotic cardiovascular disease (CVD) and the causative role of LDL has been demonstrated in several studies. Lp(a) is a subclass of LDL and elevated Lp(a) is an independent risk-factor, primarily genetically mediated. Genetic data support that high Lp(a) causes atherosclerosis. Elevated triglycerides in plasma are associated with increased risk for CVD. Whether triglycerides directly induce atherogenesis is still unclear, but current data strongly support that remnant particles from triglyceride-rich lipoproteins are causal. HDL are lipoproteins that have been considered to be important for reversed cholesterol transport. Low HDL is a strong risk-factor for CVD. However, the causative role of HDL is debated and intervention studies to raise HDL have not been successful. Reduction of LDL is the main target for prevention and treatment, using drugs that inhibit the enzyme HMG-CoA reductase, i.e. statins. Other drugs for LDL reduction and to modify other lipoproteins may further reduce risk, and new therapeutic targets are explored.
8
Reiner, Željko, Olov Wiklund, and John Betteridge. Lipids. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656653.003.0015.
Full textAbstract:
Dyslipidaemia, particularly elevated low-density lipoprotein (LDL) cholesterol, is one of the most important risk factors for cardiovascular disease (CVD). Low concentrations of high-density lipoprotein (HDL) cholesterol are independently associated with high CVD risk, while moderately elevated triglycerides are considered to be a marker of increased CVD risk. The presence of dyslipidaemias secondary to other conditions must be excluded before beginning treatment. All patients with familial hypercholesterolaemia are at high risk and should be treated by lipid-lowering therapy. Lifestyle changes are the backbone of treatment for dyslipidaemia. Statins are recommended as the first-line drugs for hypercholesterolaemia while fibrates are used primarily to decrease elevated triglycerides. If the treatment targets cannot be reached by monotherapy with lipid-lowering drugs, combination treatment may be needed.
9
Twisk, Jos, and Isabel Ferreira. Physical activity, physical fitness, and cardiovascular health. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199232482.003.0025.
Full textAbstract:
The incidence of morbidity and mortality related to CVD is rather low in a paediatric population. Studies investigating the relationship between physical activity, physical fitness, and cardiovascular health in children and adolescents are therefore mostly limited to CVD risk factors as outcome measures. For this reason, this chapter will focus on the association of physical activity and physical fitness with CVD risk factors in children and adolescents. These risk factors can be divided into the so-called traditional CVD risk factors; that is, lipoproteins [total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG)], blood pressure, body fatness, and diabetes, and ‘new’ CVD risk factors; that is, other lipoproteins [lipoprotein(a) (Lp(a)), apolipoprotein (apo)B, and apoA-1], coagulation and inflammation markers [fibrinogen, C-reactive protein (CRP)], homocysteine, and heart rate variability.
Book chapters on the topic "LDL/HDL"
1
Qin, Shucun. "LDL and HDL Oxidative Modification and Atherosclerosis." In Advances in Experimental Medicine and Biology, 157–69. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-6082-8_10.
Full text
2
Kaplan, Marielle, Michael Aviram, and Tony Hayek. "Lipoprotein (LDL and HDL) Oxidation in Diabetes Mellitus." In Contemporary Diabetes, 187–201. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7554-5_9.
Full text
3
Navab, Mohamad, Susan Y. Hama, Alan C. Wagner, Greg Hough, Andrew D. Watson, Srinivasa T. Reddy, Brian J. Van Lenten, Hillel Laks, and Alan M. Fogelman. "Protective Action of HDL-Associated PON1 Against LDL Oxidation." In Paraoxonase (PON1) in Health and Disease, 125–36. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-1027-7_6.
Full text
4
Strang, A. C., and M. D. Trip. "Wat is belangrijker: een hoog HDL of een laag LDL?" In De meest gestelde vragen over: cholesterol, 48–54. Houten: Bohn Stafleu van Loghum, 2010. http://dx.doi.org/10.1007/978-90-313-7508-0_6.
Full text
5
Barter, P. J., L. B. F. Chang, and O. V. Rajaram. "Factors Regulating the Distribution of Cholesterol Between LDL and HDL." In Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia, in Vivo Kinetics, 59–64. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4684-5904-3_6.
Full text
6
Schwarz, Margrit, and Jae B. Kim. "Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL." In Metabolic Syndrome, 199–234. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9780470910016.ch8.
Full text
7
Baudet, M. F., O. Esteva, M. Lasserre, and B. Jacotot. "Cultured Fibroblast Interactions with LDL and HDL from Healthy Subjects on Various Dietary Fats." In Advances in Experimental Medicine and Biology, 189–94. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-1268-0_27.
Full text
8
Stein, Yechezkiel, and Olga Stein. "Fate of Cholesteryl Linoleyl Ether Injected Into Rats as Chylomicrons, Acetylated LDL and HDL." In Drugs Affecting Lipid Metabolism VIII, 37–46. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-2459-1_4.
Full text
9
Kostner, Gerhard M., Gabriele Knipping, Johanna E. M. Groener, Rudolf Zechner, and Hans Dieplinger. "The Role of LCAT and Cholesteryl Ester Transfer Proteins for the HDL and LDL Structure and Metabolism." In Advances in Experimental Medicine and Biology, 79–86. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-1268-0_12.
Full text
10
Dachet, Christiane, Claude Motta, Danièle Neufcour, and Bernard Jacotot. "Modifications in the Chemical Composition and Thermometric Behavior of LDL and HDL by Probucol in Type IIa Hyperlipoproteinemia." In Advances in Experimental Medicine and Biology, 179–84. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-0733-4_22.
Full textConference papers on the topic "LDL/HDL"
1
Prabhu, Anmiv S., Alejandro Moraga, Michael Cecchini, Rafael Mulero, Stephen Olsen, Young I. Cho, and Min Jun Kim. "Synthetic Nanoscale Architectures for Lipoprotein Separation." In ASME 2008 International Mechanical Engineering Congress and Exposition. ASMEDC, 2008. http://dx.doi.org/10.1115/imece2008-66535.
Full textAbstract:
Current low density lipoprotein (LDL) apheresis procedures are expensive and time consuming. We report here a novel technique to detect and separate nanoparticles using solid state nanopores. Our technique relies on the resistive pulse phenomenon used in coulter counters. We used a 150nm diameter nanopore to detect nanoparticles that closely resembled HDL and LDL in terms of their size and surface charge. Statistical analysis of the translocation data revealed that our setup preferentially allowed the particles resembling HDL to pass thorough while restricting the translocation of the particles that resembled LDL.
2
Surya, I. E., and J. W. N. Akkerman. "HUMAN PLASMA PAF-ACETYLHYDROLASE, NORMALLY PRESENT IN LOW DENSITY LIPOPROTEINS, IS ASSOCIATED WITH HIGH DENSITY LIPOPROTEINS IN A PATIENT WITH LDL DEFICIENCY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642882.
Full textAbstract:
Platelet Activating Factor (l-0-alkyl-2-acetyl-sn-glycerol-3-phosphocholine; PAF) plays an important role in allergic and inflammatory reactions and activates platelets in the nanomolar range. One of the main factors that controls PAF activity in blood is an enzyme that hydrolyzes the acetyl-chain thereby converting PAF to biologically inactive lyso-PAF. The enzyme is acid labile and normally associated with apo B-containing low density lipoproteins (LDL, density 1,006-1,063 g/ml).We investigated whether a deficiency in LDL would affect the enzyme activity. PAF-inactivating activity was measured in plasma from a patient with abetalipoproteinemia, a rare autosomal recessive disorder, characterized by the absence of apo B and apo B-containing lipoproteins (chylomicrons, VLDL and LDL). Plasma triglyceride was 0,2 mmol/1 (normal 1,40-2,20 mmol/1) and cholesterol 1,3 mmol/1 (normal 5,60-7,70 mmol/1). Separation of lipoproteins by density gradient centrifugation revealed a slightly decreased HDL content whereas VLDL and LDL were below the detection limit (0,20 mmol/1; based on cholesterol content).Despite the absence of LDL, PAF-inactivating activity in plasma of the patient (measured by (1) the decrease in aggregation inducing activity of PAF after incubation, (ii) the conversion of 3H-acyl-PAF to lysa PAF, separated on TLC, (iii) the liberation of 3H-label from 3H-acetyl PAF) was present and even slightly higher than in normal plasma (hydrolysis of 3 3H-PAF after 20 minutes incubation was 78 ± 4% and 65 ± 6% in patient and normals, respectively, n = 4). Subfractionation revealed that the enzyme activity was present in fractions with densities of 1,065-1,214 g/ml, which are typical for HDL.These results indicate that PAF-acetylhydrolase, although normally present in LDL, binds to HDL in a patient with extreme LDL-deficiency.Supported by the Dutch Heart Foundation (grant 85082)
3
Liu, Yvonne, Johann-Georg Hocher, Shujuan Ma, Liang Hu, Huijun Chen, Xiaoli Zhang, Fei Gong, Bernhard Krämer, Ge Lin, and Berthold Hocher. "LDL/HDL- und Gesamtcholesterol/HDL-Quotienten vor der Schwangerschaft sind starke Prädiktoren für Gestationsdiabetes bei künstlicher Befruchtung." In Diabetes. Umwelt. Leben. Perspektiven aus allen Blickwinkeln. Georg Thieme Verlag KG, 2024. http://dx.doi.org/10.1055/s-0044-1785424.
Full text
4
Prabhu, Anmiv S., Talukder Zaki Jubery, Kevin Freedman, Rafael Mulero, Prashanta Dutta, and Min Jun Kim. "High Throughput Nanofluidic Architectures for Nanoparticle Separation." In ASME 2009 International Mechanical Engineering Congress and Exposition. ASMEDC, 2009. http://dx.doi.org/10.1115/imece2009-10649.
Full textAbstract:
High blood cholesterol levels and associated complications are a major health concern the world over and current techniques to deal with this, especially low density lipoprotein (LDL) apheresis, have significant room for improvement. We had previously reported a proof of concept technique that relies on silicon nitride based solid state nanopores to separate high density lipoprotein (HDL) like particles from LDL like particles. A mathematical model to describe the setup is reported. This model revealed that charge density of the pore surface was critical in determining the efficiency of separation. Accordingly we chemically modified our nanopores with (3-aminopropyl)-triethoxysilane (APTES) to achieve more efficient, high throughput particle separation. Such a technique could make it possible to develop safe and affordable LDL apheresis devices in the future.
5
Ilea, Mihai, Marius Turnea, Calin Corciova, and Mariana Rotariu. "AN E-LEARNING TOOL FOR MATHEMATICAL MODEL OF CHOLESTEROL HOMEOSTASIS DEPENDING ON DIET AND AGES." In eLSE 2020. University Publishing House, 2020. http://dx.doi.org/10.12753/2066-026x-20-200.
Full textAbstract:
The human health has many important aspects and the cholesterol regulation is one of them. The low-density lipoproteins cholesterol (LDL-C) transports plasma cholesterol (about 60%) and it is responsible by its depositing on arteries for atherosclerotic process, increasing the probability of cardiovascular events. High-density lipoproteins (HDL) can reduce this process by transport about 30% of plasma cholesterol. The balance is modified in the process of aging and depend also of other factors as diet, and physical exercises. An educational tool is proposing that use basically two mathematical models: (1) a simple one by two compartment model proposed by Wona & Hrydziuszko that include an dietary term, and (2) a more complex one that include the mechanism of simulation of aging proposed by Mc Auley. The values of parameters for both models are taken from literature and the user can modify them in order to test and simulated the models. The diet is modeled in the first model as an additive variable, and other variable are deduced from stability analysis and are assumed based on heuristic trials. In the second model, the mechanism of aging is simulated empirically (because the complete mechanism is not known yet) by increasing the LDL-C values and decreasing the number of hepatic LDL receptors (HLDLR) by decreasing the parameter that represents rate of synthesis. The tool has a library with selected curves for (HDL-C) and (LDL-C) from different countries of the world by age and sex extracted from literature. In the future development, this information will be used to model and analytic additive function for (LDL-C) curve by fitting of parameters with experimental one in system of differential equations that models the cholesterol homeostasis.
6
dos Santos Avelino Leal, Geovanna Ellen, juliana alencar, and Daniele Rodrigues Carvalho Caldas. "O EFEITO DA DIETOTERAPIA NAS DISLIPIDEMIAS E METABOLISMO DO HDL E LDL: UMA REVISÃO." In ANAIS DO 1° CONGRESSO INTERNACIONAL CIêNCIA E SOCIEDADE. Galoa, 2023. http://dx.doi.org/10.17648/cics-2023-177795.
Full text
7
Kuksis, Arnis. "Hydrolysis of hydroxy PUFA GPC of plasma lipoproteins by group IIA, V and X sPLA2s." In 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/jxxc8749.
Full textAbstract:
This study describes the isolation and identification of mono-, di- and tri-hydroxy AA, EPA and DHA in plasma LDL, HDL, HDL3 and acute phase HDL using normal phase LC/ESI/MS as previously reported for plasma lipoprotein GPC epoxides and isoprostanes. The lipoproteins contained variable amounts of the hydroxy PUFA GPC (1 to 10 nanomoles/mg protein), likely the product of lipid peroxidation and the action of various lipoxygenases and cytochrome P450 enzymes on both free fatty acids and the parent GPCs, although transesterification by preformed hydroxy fatty acids was not excluded. The hydroxy PUFA GPC was hydrolyzed to variable extent (20-90%) by the different-PLA2s, with group IIA sPLA2 showing the lowest and group X sPLA2 the highest activity. Although standards were not available and detailed identification of the structure was not performed, there was general agreement between the masses determined for the identified structures and masses calculated for the GPC equivalents of the resolvins, protectins and maresins, as reported in the literature. There has been no biological testing of the GPC esters of the specialized pro-resolving mediators.
8
Gomes, Karina, Maria Carvalho, Ramon Pereira, Henrique Guimarães, Antônio Teixeira, Alexandre Braga, Maira Barbosa, Wagner Junior, and Paulo Caramelli. "MACHINE LEARNING-BASED ROUTINE LABORATORY VARIABLES SCREENING FOR ONE-YEAR COGNITIVE AND FUNCTIONAL DECLINE IN INDIVIDUALS AGED 75+ YEARS: THE PIETÀ STUDY." In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda004.
Full textAbstract:
Background: Cognitive and functional decline are important health problems in older adults. Objectives: To investigate Machine Learning (ML) algorithms of routine laboratory variables in predicting cognitive and functional decline in a population-based sample aged 75+ years within one-year. Methods: 132 individuals were selected from a population-based project. Functional and cognitive performances were evaluated at baseline and one year after. Results of routine laboratory tests obtained at baseline were used to generate three ML algorithms. Results: Random forest (RF), including triglycerides, glucose, hematocrit, RDW, albumin, hemoglobin, globulin, HDL, TSH, creatinine, lymphocyte, erythrocyte, platelet/leucocyte (PLR) and neutrophil/leucocyte (NLR) ratios, ALT, leukocyte, LDL, cortisol, GGT and eosinophil, showed the best performance to predict the cognitive decline (accuracy = 0.80). For functional decline (accuracy =0.92), the most important RF variables were platelet, PLR and NLR, hemoglobin, globulin, cortisol, RDW, glucose, basophil, B12 vitamin, creatinine, GGT, ALT, AST, eosinophil, hematocrit, erythrocyte, triglycerides, HDL and monocyte. Conclusions: Our results suggest that ML presents a good accuracy to predict cognitive and functional decline in oldest-old subjects using routine laboratory variables.
9
FATHIL, Noor Mahdi. "EFFECT OF THE ENERGY DRINK (TIGER) ON THE PARAMETERS OF LIPID PROFILEIN THE FEMALE ALBINO MICE." In III.International Scientific Congress of Pure,Appliedand Technological Sciences. Rimar Academy, 2021. http://dx.doi.org/10.47832/minarcongress3-5.
Full textAbstract:
The aim of research is to clarify effect of an energy drink (Tiger) on Lipid profile physiological parameters in female mice for a period of four weeks. Adults female mice were used in research and divide to two groups. The first group is the control group that give distilled water (D.w.) for four weeks and the second group was treated group with tiger concentration dose 1.5 ml/mg for period of four weeks. After the end of the dosing period, sacrifices animals and the blood samples are collected without anticoagulant, and blood serum is obtained and kept at− 20 °C for biochemical tests. The research was seen that there was the significant increase (p<0.05) in a cholesterol and the highdensity lipoproteins, with a significant decrease (p< 0.05) in value of triglycerides and a very low-density lipoprotein(VLDL), a Low density lipoprotein (LDL) was showed non –significant (P≥0.05) in the dosed group as compare as the control group. Key words: Energy Drink (Tiger ), Cholesterol(CHO), Triglycerides (TG), HighDensity Lipoprotein (HDL), Very Low-Density Lipoprotein (VLDL), The (LDL) Low-Density Lipoprotein.
10
McEwen, Tim, John Flach, and Nancy Elder. "Ecological Interface for Assessing Cardiac Disease." In ASME 2012 11th Biennial Conference on Engineering Systems Design and Analysis. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/esda2012-82974.
Full textAbstract:
Using the ecological interface design approach, a graphical user interface was developed to show how different factors (e.g., LDL, HDL, triglycerides, systolic blood pressure) contribute to cardiac health. The display is based on an epidemiological model derived from the Framingham study and additional treatment guidelines in the medical literature. This interactive display allows physicians and patients to see how different factors contribute to overall cardiac health and to see the impact of interventions on reducing risk. The display also graphically associates the state of the patient with treatment categories to help physicians to select the best treatment method based on empirical models. It also has the potential to enrich the dialogue between physician and patient through interactive ‘experiments’ that illustrate the potential benefits of various treatment options.
Reports on the topic "LDL/HDL"
1
Cortés Ortigosa, Francisco, and María Pascual Mora. Characterization of the extraction method of extracellular vesicles by HDL and LDL contamination. Fundación Avanza, May 2023. http://dx.doi.org/10.60096/fundacionavanza/2902022.
Full textAbstract:
In this study we assess and validate the method of extraction of extracellular vesicles found in blood plasma with commercial kits to exclude potential contamination by plasma HDL and LDL particles using immunoblot analysis.
2
Hung, Hsuan-Yu, Hui-Hsiung Lai, Hui-Chuan Lin, and Chung-Yu Chen. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0055.
Full textAbstract:
Review question / Objective: P: ("Hepatitis C"[Mesh] AND "Hepacivirus"[Mesh] AND "Hepatitis C, Chronic”[Mesh]) I: (direct acting antiviral OR asunaprevir OR boceprevir OR daclatasvir OR dasabuvir OR elbasvir OR glecaprevir OR grazoprevir OR ledipasvir OR ombitasvir OR paritaprevir OR pibrentasvir OR simeprevir OR sofosbuvir OR telaprevir OR velpatasvir OR voxilaprevir) C: placebo O: ( "Cholesterol, VLDL"[Mesh] OR "Cholesterol, LDL"[Mesh] OR "Cholesterol, HDL"[Mesh] OR "Dyslipidemias"[Mesh] OR "lipoprotein cholesterol ester, human" [Supplementary Concept] OR "lipoprotein cholesterol" [Supplementary Concept] ) OR ((lipoprotein cholesterol) OR ("lipidemia") OR (lipid metabolism) OR (lipid)). Information sources: We conducted a comprehensive literature search of PubMed, Cochrane Library, Embase, and Ovid MEDLINE electronic databases from their inception to May 20, 2022.
3
Zhao, Shaoping, Jiao Zhong, Caihong Sun, and Junping Zhang. Effects of Aerobic Exercise on TC, HDL-C, LDL-C and TG in patients with hyperlipidemia : A protocol of Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2021. http://dx.doi.org/10.37766/inplasy2021.2.0037.
Full text
4
Gao, Hui, Chen Gong, Shi-chun Shen, Jia-ying Zhao, Dou-dou Xu, Fang-biao Tao, Yang Wang, and Xiao-chen Fan. A systematic review on the associations between prenatal phthalate exposure and childhood glycolipid metabolism and blood pressure: evidence from epidemiological studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0111.
Full textAbstract:
Review question / Objective: The present systematic review was performed to obtain a summary of epidemiological evidence on the relationships of in utero exposure to phthalates with childhood glycolipid metabolism and blood pressure. Condition being studied: Childhood cardiovascular risk factors including blood pressure, lipid profile (e.g., triglycerides, total cholesterol, HDL−C, LDL−C) and glucose metabolism (e.g., insulin, insulin resistance, insulin sensitivity, glucose) were the interested outcomes. Eligibility criteria: In brief, epidemiological studies including cohort study, case-control study and cross-sectional survey were screened. Studies regarding relationships between human exposure to organophosphate esters and neurotoxicity were possible eligible for the present systematic review. The adverse neurodevelopmental outcomes included development of cognition, behavior, motor, brain change, emotion, etc. Studies that did not meet the above criteria were not included in this systematic review.
5
Chen, Jiankun, Yingming Gu, Lihong Yin, Minyi He, Na Liu, Yue Lu, Changcai Xie, Jiqiang Li, and Yu Chen. Network meta-analysis of curative efficacy of different acupuncture methods on obesity combined with insulin resistance. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2022. http://dx.doi.org/10.37766/inplasy2022.8.0075.
Full textAbstract:
Review question / Objective: Population：Patients diagnosed as obesity with insulin resistance. Obesity reference: Consensus of experts on the Prevention and treatment of adult obesity in China in 2011 and Consensus of Chinese experts on medical nutrition therapy for overweight/obesity in 2016 were developed by the Obesity Group of Chinese Society of Endocrinology(CSE); BMI≥28. IR reference: According to the Expert opinions on insulin resistance evaluation published by Chinese Diabetes Society, HOMA-IR≥2.68 is regarded as the standard for the diagnosis of IR. Regardless of age, gender and course of disease. Patients diagnosed as obesity with insulin resistance. Intervention：Any kind of acupuncture, moxibustion, acupuncture+moxibustion, warm acupuncture, electropuncture, auricular point, acupoint application and acupoint catgut embedding. Comparison：Other acupuncture treatments, Drug therapy or blank control. Outcome：Primary outcomes: ①Fasting blood-glucose (FBG); ②Fasting serum insulin (FINS); ③Homeostasis model assessment-IR (HOMA-IR); ④Body Mass Index (BMI). Secondary outcomes: ①Waistline; ②Waist-hip ratio;③Triglyceride (TG); ④Total cholesterol (TC); ⑤High-density lipoprotein (HDL); ⑥Low-density lipoprotein (LDL). Study: Randomized controlled trials (RCTs) of different acupuncture methods in the treatment on obesity with insulin resistance, blind method and language are not limited. Randomized controlled trials (RCTs).